Patricia DeFusco

686 total citations
16 papers, 335 citations indexed

About

Patricia DeFusco is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Patricia DeFusco has authored 16 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Cancer Research. Recurrent topics in Patricia DeFusco's work include Cancer Treatment and Pharmacology (7 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Patricia DeFusco is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Patricia DeFusco collaborates with scholars based in United States and Canada. Patricia DeFusco's co-authors include Quing Zhu, Poornima Hegde, Andrew Ricci, Susan Tannenbaum, Eleftherios P. Mamounas, James D. Bearden, Stuart J. Tipping, Michael P. Thirlwell, Roy E. Smith and Barry C. Lembersky and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

Patricia DeFusco

15 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patricia DeFusco United States 6 167 107 97 78 63 16 335
Jingming Ye China 12 205 1.2× 103 1.0× 196 2.0× 12 0.2× 14 0.2× 56 388
Nana Scotto Switzerland 7 246 1.5× 99 0.9× 50 0.5× 8 0.1× 10 0.2× 15 333
Anne Favret United States 8 272 1.6× 41 0.4× 132 1.4× 9 0.1× 24 0.4× 16 365
Patrick Chan Singapore 12 112 0.7× 36 0.3× 207 2.1× 18 0.2× 9 0.1× 32 445
Nicholas C. Richardson United States 7 93 0.6× 31 0.3× 22 0.2× 14 0.2× 22 0.3× 16 253
Gary Shelton United States 8 200 1.2× 54 0.5× 93 1.0× 7 0.1× 66 1.0× 14 477
Yukako Ohno Japan 11 91 0.5× 18 0.2× 160 1.6× 12 0.2× 35 0.6× 26 317
C Vogel United States 6 302 1.8× 67 0.6× 128 1.3× 6 0.1× 7 0.1× 8 332
Daniel Krell United Kingdom 10 146 0.9× 34 0.3× 178 1.8× 7 0.1× 11 0.2× 16 369
Sue Chua United Kingdom 9 147 0.9× 199 1.9× 42 0.4× 22 0.3× 6 0.1× 21 369

Countries citing papers authored by Patricia DeFusco

Since Specialization
Citations

This map shows the geographic impact of Patricia DeFusco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia DeFusco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia DeFusco more than expected).

Fields of papers citing papers by Patricia DeFusco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia DeFusco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia DeFusco. The network helps show where Patricia DeFusco may publish in the future.

Co-authorship network of co-authors of Patricia DeFusco

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia DeFusco. A scholar is included among the top collaborators of Patricia DeFusco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia DeFusco. Patricia DeFusco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Yu, Anthony F., Chau T. Dang, Chaya S. Moskowitz, et al.. (2025). Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy. JACC CardioOncology. 7(4). 430–441. 4 indexed citations
2.
Yu, Anthony F., Chau T. Dang, Chaya S. Moskowitz, et al.. (2023). Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-Oncology. 9(1). 13–13. 4 indexed citations
3.
Yu, Anthony F., Chau T. Dang, Chaya S. Moskowitz, et al.. (2023). Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.. Journal of Clinical Oncology. 41(16_suppl). 12083–12083. 1 indexed citations
4.
Traina, Tiffany A., Lee W. Jones, Victoria Blinder, et al.. (2020). Abstract P5-12-09: Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. Cancer Research. 80(4_Supplement). P5–12. 2 indexed citations
5.
6.
Traina, Tiffany A., Sujata Patil, Marcia Edelweiss, et al.. (2019). Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC.. Journal of Clinical Oncology. 37(15_suppl). 546–546. 4 indexed citations
7.
Zhu, Quing, Susan Tannenbaum, Scott H. Kurtzman, et al.. (2018). Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters. Breast Cancer Research. 20(1). 56–56. 18 indexed citations
8.
Iyengar, Neil M., Diana Lake, Ayca Gucalp, et al.. (2017). Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy. Annals of Oncology. 28. v81–v81. 1 indexed citations
9.
Iyengar, Neil M., Lillian M. Smyth, Diana Lake, et al.. (2016). Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy. Annals of Oncology. 27. vi84–vi84. 2 indexed citations
10.
Zhu, Quing, Liqun Wang, Susan Tannenbaum, et al.. (2014). Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. Breast Cancer Research. 16(5). 456–456. 32 indexed citations
11.
Zhu, Quing, Patricia DeFusco, Andrew Ricci, et al.. (2012). Breast Cancer: Assessing Response to Neoadjuvant Chemotherapy by Using US-guided Near-Infrared Tomography. Radiology. 266(2). 433–442. 73 indexed citations
12.
Zhu, Quing, Patricia DeFusco, Susan Tannenbaum, et al.. (2010). Optical Tomography Using US Localization to Assess Response to Neoadjuvant Chemotherapy. 26. BSuB7–BSuB7.
13.
Zhu, Quing, M. Kane, Stacey L. Tannenbaum, et al.. (2009). Tumor angiogenesis imaged by optical tomography can accurately diagnose early-stage invasive breast cancers.. Cancer Research. 69(2_Supplement). 52–52. 1 indexed citations
14.
Smith, Roy E., Ann Brown, Eleftherios P. Mamounas, et al.. (1999). Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. Journal of Clinical Oncology. 17(11). 3403–3411. 129 indexed citations
15.
Laughlin, Mary J., Dean McGaughey, Nelson J. Chao, et al.. (1998). Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.. Journal of Clinical Oncology. 16(3). 1008–1012. 57 indexed citations
16.
Sweeney, Kevin, et al.. (1991). Influence of Sucralfate on Trilisate Bioavailability. The Journal of Clinical Pharmacology. 31(4). 377–379. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingming Ye Breakdown of academic impact, for papers by Nana Scotto Breakdown of academic impact, for papers by Anne Favret Breakdown of academic impact, for papers by Patrick Chan Breakdown of academic impact, for papers by Nicholas C. Richardson Breakdown of academic impact, for papers by Gary Shelton Breakdown of academic impact, for papers by Yukako Ohno Breakdown of academic impact, for papers by C Vogel Breakdown of academic impact, for papers by Daniel Krell Breakdown of academic impact, for papers by Sue Chua
Rankless by CCL
2026